 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Jul 31, 2024
P3, N=10, Active, not recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Apr 2024 --> Sep 2024
- || tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Feb 2, 2024
P3, N=15, Completed, Sponsor: AB2 Bio Ltd.
Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Apr 2024 --> Sep 2024 Active, not recruiting --> Completed
- tadekinig alfa (IL-18BP) / AB2 Bio
Enrollment closed: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Nov 8, 2023
P3, N=10, Active, not recruiting, Sponsor: AB2 Bio Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Nov 3, 2023
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Recruiting --> Active, not recruiting Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
- | tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jul 21, 2023
P3, N=15, Active, not recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Nov 2023 --> Apr 2024 Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Oct 2023
- || tadekinig alfa (IL-18BP) / AB2 Bio
Enrollment closed: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Mar 10, 2023
P3, N=15, Active, not recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Oct 2023 Recruiting --> Active, not recruiting
- | tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Cytokine release syndrome: Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome (clinicaltrials.gov) - Feb 3, 2023
P1, N=10, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
- ||||| tadekinig alfa (IL-18BP) / AB2 Bio
Enrollment change, Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jul 27, 2022
P3, N=15, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Jan 2023 --> Jan 2025 N=10 --> 15 | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: May 2022 --> May 2023
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Jul 23, 2022
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
N=10 --> 15 | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: May 2022 --> May 2023 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
- | tadekinig alfa (IL-18BP) / AB2 Bio
Biomarker, Journal: Interleukin-18: a biomarker with therapeutic potential in adult-onset Still's disease. (Pubmed Central) - Jul 23, 2022
IL-18 binding protein (IL-18BP) negatively regulates the biological activity of IL-18 by inhibiting IL-18 signaling, and a clinical trial revealed that IL-18BP (Tadekining alfa) treatment was well-tolerated and effective for AOSD. Recently, monoclonal antibodies against IL-18 have been under evaluation in a phase 1b trial.
- ||| tadekinig alfa (IL-18BP) / AB2 Bio
IL-18, Iike IL-1, is a produced by activation of the inflammasome. IL-18 is a potential bioimarker for #AOSD, closely linked to Dz activity & could be a Tx target, either as IL-18 binding protein (Tadekinig alfa) or mAb against IL-18 (phase 1b) https://t.co/ex231f27rg (Twitter) - Jul 7, 2022
- | tadekinig alfa (IL-18BP) / AB2 Bio
Enrollment open, CAR T-Cell Therapy, Cytokine release syndrome: Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome (clinicaltrials.gov) - Jul 7, 2022
P1, N=10, Recruiting, Sponsor: University of Pennsylvania
Recently, monoclonal antibodies against IL-18 have been under evaluation in a phase 1b trial. Not yet recruiting --> Recruiting
- | tadekinig alfa (IL-18BP) / AB2 Bio
Journal: A Case of XIAP Deficiency Successfully Managed with Tadekinig Alfa (rhIL-18BP). (Pubmed Central) - Jun 9, 2022
Not yet recruiting --> Recruiting No abstract available
- | Journal: Current treatment options for monogenic periodic fever syndromes - the role of interleukin 1 inhibitors. (Pubmed Central) - Apr 7, 2022
Moreover, several clinical trials are currently underway with other very promising drugs, such as gevokizumab, tadekinig alfa or tranilast. In the following review, we provide a new perspective on the efficacy and safety of IL-1 inhibitors that have provided the novel results coming from recently published clinical trials.
- | tadekinig alfa (IL-18BP) / AB2 Bio
New P1 trial, CAR T-Cell Therapy, Cytokine release syndrome: Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome (clinicaltrials.gov) - Mar 31, 2022
P1, N=10, Not yet recruiting, Sponsor: University of Pennsylvania
- || Clinical, Review, Journal: Update on the therapy of adult-onset Still's disease with a focus on IL-1-inhibition: a systematic review. (Pubmed Central) - Dec 7, 2021
The overall efficacy-safety profile of the IL-1 inhibitors is favorable reflecting a targeted approach as standard of care. We can expect that the successful treatment of AOSD with IL-1 inhibition will facilitate further clinical and basic research with impact on other auto-inflammatory and hyper-inflammatory conditions.
- || Review, Journal: IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives. (Pubmed Central) - Jun 23, 2021
Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Apr 22, 2021
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes. Trial completion date: Feb 2022 --> Jan 2023 | Trial primary completion date: Jun 2021 --> Nov 2022
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Apr 22, 2021
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Feb 2022 --> Jan 2023 | Trial primary completion date: Jun 2021 --> Nov 2022 Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> May 2022
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Journal: Current treatment options and safety considerations when treating adult-onset Still's disease. (Pubmed Central) - Mar 18, 2021
IL-1 and IL-6 blockade are effective in treating systemic and articular inflammation of AOSD patients. IL-1 blockade also has an excellent safety profile and therefore represent the first choice of biologic treatment in this clinical scenario.
- || Review, Journal: Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now? (Pubmed Central) - Mar 13, 2021
However, other promising agents, such as gevokizumab, IL-1β blocking monoclonal antibody, tadekinig alfa, a human recombinant IL-18-binding protein, and tranilast, an analog of a tryptophan metabolite, are currently being tested...Furthermore, the anti-IL-1 therapy allowed corticosteroid tapering and, in some cases, even withdrawal. This article reviews the current IL-1 inhibitors and the results of all clinical trials in which they have been tested for the management of broad spectrum of polygenic AIDs.
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jan 14, 2021
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
This article reviews the current IL-1 inhibitors and the results of all clinical trials in which they have been tested for the management of broad spectrum of polygenic AIDs. Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Oct 2021
- || tadekinig alfa (IL-18BP) / AB2 Bio
$WXXWY WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa https://t.co/HwUzSqiWqE (Twitter) - Oct 29, 2020
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jun 9, 2020
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Oct 2021 Trial completion date: Nov 2020 --> May 2021 | Trial primary completion date: Sep 2020 --> Dec 2020
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Jun 9, 2020
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Nov 2020 --> May 2021 | Trial primary completion date: Sep 2020 --> Dec 2020 Trial completion date: Jul 2020 --> Feb 2022 | Trial primary completion date: Mar 2020 --> Jun 2021
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jan 8, 2020
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Jul 2020 --> Feb 2022 | Trial primary completion date: Mar 2020 --> Jun 2021 Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Nov 2019 --> Sep 2020
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jan 25, 2019
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Nov 2019 --> Sep 2020 Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: May 2019 --> Nov 2019
- | tadekinig alfa (IL-18BP) / AB2 Bio
New P3 trial: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension (clinicaltrials.gov) - Apr 30, 2018
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
- tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion date, Trial primary completion date: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Apr 9, 2018
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: May 2019 --> Nov 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> May 2019
- tadekinig alfa (IL-18BP) / AB2 Bio
Enrollment open: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jun 16, 2017
P3, N=10, Recruiting, Sponsor: AB2 Bio Ltd.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> May 2019 Active, not recruiting --> Recruiting
- tadekinig alfa (IL-18BP) / AB2 Bio
Enrollment closed: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (clinicaltrials.gov) - Jun 14, 2017
P3, N=10, Active, not recruiting, Sponsor: AB2 Bio Ltd.
Active, not recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- | tadekinig alfa (IL-18BP) / AB2 Bio
Trial completion, Enrollment change: Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease (clinicaltrials.gov) - Aug 30, 2016
P2, N=23, Completed, Sponsor: AB2 Bio Ltd.
Not yet recruiting --> Active, not recruiting Recruiting --> Completed | N=30 --> 23
- tadekinig alfa (IL-18BP) / AB2 Bio
New P2 trial: Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease (clinicaltrials.gov) - Mar 25, 2015
P2, N=30, Recruiting, Sponsor: AB2 Bio Ltd.